Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Lorlatinib extended PFS and improved time to intracranial progression vs crizotinib in patients with ALK-positive non–small cell lung cancer.

Lorlatinib Yields Longest Reported PFS in Advanced NSCLC

Frontline rivoceranib plus camrelizumab continued to show a significant improvement in OS vs sorafenib in advanced unresectable hepatocellular carcinoma.

Rivoceranib Plus Camrelizumab Maintains Frontline Survival Benefit in Unresectable HCC

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Here is your guide to important regulatory approvals made by the FDA in May 2024.

OncLive’s May Roundup of Key FDA Approvals in Oncology

A new study may open life-saving opportunities for Hispanic patients, who are one-third less likely to find a fully matched donor from the national registry than white patients.

Half-Matched Family Donors Offer Best Outcomes for Hispanic Patients Undergoing Bone Marrow Transplants

Ivonescimab monotherapy improved PFS vs pembrolizumab in the first-line treatment of PD-L1–positive NSCLC in China.

First-Line Ivonescimab Improves PFS vs Pembrolizumab in PD-L1+ NSCLC in China

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma. 

FDA Accepts BLA Resubmission for Zolbetuximab in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Evolving Treatment Strategies in High-Risk Neuroblastoma

Videos

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Giselle Sholler, MD, provides an overview of neuroblastoma, highlighting that 50% of all diagnosed cases in the US are considered high-risk, with a relapse rate of over 40%.

An Overview of Neuroblastoma

Anurag Agrawal, MD, explains his approaches to diagnosing neuroblastoma, including urine markers, imaging, and bone marrow sampling, and emphasizes age and disease dissemination as major prognostic indicators alongside genetic predisposition and treatment response.

Approaches to Diagnosing Neuroblastoma

Dr Giselle Sholler details the role of CURIE scores in measuring bone disease and metastatic spread in neuroblastoma, with a score greater than 12 indicating a worse prognosis.

Role of CURIE Scores in the Treatment and Management of Neuroblastoma

Giselle Sholler, MD, outlines the currently available treatment options for neuroblastoma based on a patient’s risk status.

Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

Anurag Agrawal, MD, discusses how refractory and relapsed neuroblastoma is differentiated, and the typical treatment approaches for both.

Differentiating Refractory and Relapsed Neuroblastoma

Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.

Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.

Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.

Future Perspectives in the Treatment of Neuroblastoma

Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP: 1.An Overview of Neuroblastoma

EP: 2.Approaches to Diagnosing Neuroblastoma

EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP: 5.Differentiating Refractory and Relapsed Neuroblastoma

EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP: 10.Future Perspectives in the Treatment of Neuroblastoma

Latest Conference Coverage